Loading news...
Si-Bone (SIBN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.
SI-BONE, Inc. (SIBN) Q4 2025 Earnings Call Transcript
Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025
SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time.
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of SiBone (NASDAQ: SIBN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy
SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026.
Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20%
SI-Bone shares rose in after-hours trading as three executives sold stock last week to cover RSU tax obligations.
SiBone (NASDAQ: SIBN - Get Free Report) CFO Anshul Maheshwari sold 18,542 shares of SiBone stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $20.15, for a total value of $373,621.30. Following the sale, the chief financial officer directly owned 185,231 shares in the company, valued
SiBone (NASDAQ: SIBN - Get Free Report) SVP Michael Pisetsky sold 19,600 shares of the business's stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $20.15, for a total value of $394,940.00. Following the sale, the senior vice president owned 231,896 shares in the company, valued at approximately
SiBone (NASDAQ: SIBN - Get Free Report) hit a new 52-week high on Thursday after Truist Financial raised their price target on the stock from $21.00 to $23.00. Truist Financial currently has a buy rating on the stock. SiBone traded as high as $20.27 and last traded at $20.25, with a volume of 731079 shares traded.
After reaching an important support level, SiBone (SIBN) could be a good stock pick from a technical perspective. SIBN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Intech Investment Management LLC cut its stake in shares of SiBone (NASDAQ: SIBN) by 49.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,073 shares of the company's stock after selling 16,535 shares during the period. Intech Investment
AXQ Capital LP acquired a new stake in shares of SiBone (NASDAQ: SIBN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,390 shares of the company's stock, valued at approximately $290,000. Several other institutional investors and
SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, December 2, 2025, at 9:00 a.m. Pacific Time/ 12:00 p.m. Eastern Time.
Spectral Diagnostics (OTCMKTS:EDTXF - Get Free Report) and SiBone (NASDAQ: SIBN - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation. Profitability This table compares Spectral Diagnostics and SiBone's
The medical device maker posted a satisfying beat-and-raise third quarter. During the period, it managed to narrow its net loss considerably.
SI-BONE, Inc. ( SIBN ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Saqib Iqbal - Director of FP&A and Investor Relations Laura Francis - CEO & Director Anshul Maheshwari - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Gracia Mahoney - BofA Securities, Research Division Young Li - Jefferies LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division David Saxon - Needham & Company, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Presentation Operator Good afternoon, and welcome to SI-BONE's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.16 per share a year ago.